

TRADE TALK

Serial solver

IBM RESEARCH



Cristiano Malossi works at the IBM Laboratory in Zurich, Switzerland. He won an IBM Research Prize for his PhD thesis in 2013 and the ACM Gordon

Bell Prize two years later. He has used his mathematical skills to model blood flow, design aircraft, simulate convection in Earth's mantle and improve energy efficiency in high-performance computing.

Did you always want to work in industry?

I did my bachelor's and master's degrees studying aerospace, and my PhD in applied mathematics. Since the beginning of my studies, I was oriented towards a job in a company with high impact on technology. I wanted to see my work applied towards real products and services. The problems you solve in academia are generally more fundamental and long term; in a business environment, you are exposed to many different ones every day, and you are asked to get them solved almost as soon as you get them. This drives you to learn a lot of different things, very fast.

How did you find the perfect position?

At the end of my PhD, I didn't have time to send out CVs, and my professor said, 'if you want to stay as a postdoc, we welcome you', and so I stayed. I invested six months in sending out the best possible CVs to find the place I wanted to work. When you compete for the most prestigious positions, you can't send the application after half a day of working on it.

How did applying for prizes aid your search?

You show that you have high targets and that you are a great teamworker. Even if you don't win, the fact that you participated shows that you are motivated and that you want to do more than what is expected from you, which is what many companies are looking for. And I must admit, I was lucky; winning the IBM research prize for my PhD thesis on algorithms that allow patient-specific simulations of blood flow in the arteries was a strong way to get in touch with the people here. ■

INTERVIEW BY MONYA BAKER

This interview has been edited for length and clarity. See go.nature.com/li3gbs for more.

Act (and its counterpart in Scotland) regulates the use of human organs and tissues. The National Health Service (NHS) helps to direct how personal medical information can be shared. Senior members of staff in the NHS act as 'Caldicott guardians' who work to ensure that those data stay secure. "That seems like a lot of regulations, and it is," says Stefan Symeonides, a clinical oncologist at the University of Edinburgh. "My advice is to not be daunted. It's a lot of process, but the underlying principle is to enable research and maximize use of data in a safe way."

In Europe, harmonized laws facilitate the flow of tissues and data between EU member countries and beyond.

KNOTTY PROBLEMS

It can be a challenge to navigate the acquisition of health data. Large institutions and academic health-science centres in the United States and the United Kingdom typically employ or retain individuals who have expertise in privacy law and can offer comprehensive support to researchers. Madhu Purewal, a senior legal officer at the University of Texas MD Anderson Cancer Center in Houston, earlier this year helped an investigator to procure patient data from a handful of institutions that had different protocols. She guided the researcher in crafting individualized agreements for each. "As a faculty member, this is not your area of expertise," she says. "But I can help you figure out what is needed."

Carlos Caldas, an oncologist at the University of Cambridge, UK, says that he and his colleagues rely heavily on their institutions' clinical-research coordinators and data-security staff to steer them through the regulatory requirements. His advice? "Join places that have a critical mass of expertise." Caldas also says that large cancer-research facilities tend to have the infrastructure — tissue and tumour banks and encrypted databases — to accept and process samples without putting materials or data at risk.

Launching a research programme at an institution with no affiliation to a hospital can be a trickier matter. The lack of access to patients created cumbersome obstacles for biomedical engineer Michael Fenn, who works on cancer diagnostics. As a new member of faculty in 2013 at the Florida Institute of Technology in Melbourne, Fenn's research stalled when he tried to get patient samples and data from other research centres. The institute had no formal partnerships with cancer hospitals or research institutes, so he was uncertain about whom to contact at those organizations or how to comply with their privacy requirements. "I'm asking them, 'May I have some tissue from a particular type of patient?'" he says. "But the process was so convoluted and I wasn't even sure how to initiate it."

Fenn smoothed the way by establishing

relationships with key researchers, surgeons and pathologists at the centres who helped him to navigate the process of accessing tissue and data. He now advises early-career researchers to establish informal alliances before they even think about getting their first samples. "You'll get the access you need, and the scientists and physicians there will help you to move beyond the bureaucracy," he says.

Even investigators at large cancer-research centres are likely to encounter bureaucratic knots, particularly when participating in large collaborations that span institutions. "In an era of team science, that can be really difficult," Sellers says. "There might be 30 institutional review boards involved for one study, each with their own agreements. It takes time, money and effort, and it's not helping to accelerate academic health-related research."

Individual researchers can be frustrated by restrictions. Katerina Politi, a pathologist at the Yale Cancer Center in New Haven, Connecticut, has obtained consent from patients that allows her to collect their

Joining forces with peers and colleagues is the best way to untangle the knotty problems of privacy.

tissue for immediate analysis. But patients must provide further consent if another sample is needed from them. "We can do this biopsy, but if they have another in the future, they

have to consent," says Politi. "If you could streamline the consent of patients and acquisition of materials, you might not miss opportunities to learn more about diseases."

Some institutions are trying to smooth the process. In 2014, oncologist Michael Caligiuri, who directs the Ohio State University Comprehensive Cancer Center in Columbus, in 2014 co-founded the Oncology Research Information Exchange Network, a federation of 11 cancer-research centres across the United States. Member organizations share an institutional review board and follow a uniform protocol for interacting with patients and requesting and collecting tissue and data. Caligiuri says that studies performed within the network can move more quickly and require less paperwork because members can share data and samples from patients.

Ultimately, joining forces with peers and colleagues is the best way to untangle the knotty problems of privacy, say seasoned researchers. "The rules are always changing," says Sellers. "One needs to be paying attention to the literature and what's coming out there from the government. Find people in your network who are dealing with the same challenges. We're always happy to share our recipes for obtaining the data and consent." ■

Alaina Levine is a freelance science writer based in Tucson, Arizona.